Development and preclinical evaluation of tetraspecific antibodies in combination with ex vivo expanded NK cells infusion for improved control of esophageal cancer

Background

Esophageal squamous cell carcinoma (ESCC) is highly heterogeneous, leading to limited drug effectiveness and resistance. Antibody therapies offer limited benefits due to low response rates. Multispecific antibodies, targeting multiple tumor antigens and natural killer (NK)-cell receptors, may overcome these challenges, but their effectiveness in ESCC therapy is not yet understood.